论文部分内容阅读
1981年日本武田制药公司从假单胞菌的分泌物中分离得到一种新的单环结构物质,Sulfazecin和Isosulfazecin。美国施贵宝公司也从细菌的分泌物中分离得到多种含有同样单环结构的化合物,这类物质统称单环β-内酰胺菌素(Monobactam)。经过一系列化学结构改造,Sykes~[1]等研制出具有实用希望的衍生物-Aztreonam代号为SQ26776(图1),该物质对革蓝氏阴性菌具有在较低浓度下抑制或杀死细菌的能力,其主要优点表现在对各种β-内酰胺酶具有较高的稳定性,它不会被β-内酰胺酶水解而造成药物失去活性,对大肠埃氏杆菌、肺炎克氏杆菌、
In 1981 Japan Takeda Pharmaceutical Company isolated from the secretion of Pseudomonas, a new monocyclic structural substance, Sulfazecin and Isosulfazecin. The United States Squibb also isolated from the bacterial secretions of a variety of compounds containing the same monocyclic structure, these substances collectively referred to as monobactam monobactam (Monobactam). After a series of chemical structural transformation, Sykes ~ [1] and other derivatives developed with practical hope - Aztreonam code SQ26776 (Figure 1), the substance of the gram-negative bacteria with lower concentrations inhibit or kill bacteria , Its main advantage is manifested in a variety of β-lactamase with high stability, it will not be β-lactamase hydrolysis caused by the loss of drug activity on Escherichia coli, Klebsiella pneumoniae,